Confernece on PHT with FDA 1

DREYFUS MEDICAL FOUNDATION CONFERENCE ON PHT WITH FDA

February 22 and 23, 1972

Tuesday, February 22
10:00 a.m.	Background Early evidence Institutional studies (with reference to both crime and problems within the institutions): Worcester County Jail Study (double-blind) Lyman School for Boys (Juvenile Delinquents) Patuxent Institution

1:00 p.m.	Lunch
2:00 p.m.	Basic mechanisms of action of PHT: Effect on hyperexcitable nerve cell Suppression of post-tetanic potentiation Stabilization of membrane Regulatory effect on sodium and potassium Resistance to anoxia Increase of energy compounds in brain (glucose, ATP, and creatine phosphate) Stabilizing effects on labile diabetes Cerebral and coronary vessel dilatation Protection against digitalis toxicity Protection against cortisone toxicity Other antitoxic effects of interest: DDT, cyanide, alloxan, radiation, etc.

3:15 p.m.	Coffee and Discussion
3:30 p.m.	“The Broad Range of Use of PHT” Review of thought, mood, and behavior disorders (1938-1971) Discussion

5:00 p.m.	Recess
7:30 p.m.	Dinner

Wednesday, February 23
9:00 a.m.	Review of “The Broad Range of Use of PHT” Symptoms and disorders for which PHT effectiveness has been reported Discussion of cardiac uses Brief review of other somatic disorders Alcoholism and drug addiction Safety and toxicology

10:15 a.m.	Coffee
10:30 a.m.	The effects of PHT on overthinking, anger, fear, and related emotions The One-Hour test

11:30 a.m.	Recent work reporting therapeutic benefits of PHT in glaucoma, steroid myopathy, hostility in chronic psychotics, violence, radiation, shock lung, asthma, digitalis toxicity, and hypertension

12:30 p.m.	Lunch
1:30 p.m.	PHT’s value is based on the combination of many factors: Broad range of effectiveness Rapidity of action Beneficial “side effects” Not addictive Not a sedative at therapeutic doses Safety established by long period of use How PHT has been overlooked Discussion

4:00 p.m.	Conference ends

Return to Travels With the Government